The Max Foundation Establishes Unprecedented Network of Leading Cancer Providers in LMIC

The Max Foundation Establishes Unprecedented Network of Leading Cancer Providers in LMIC

In an effort to strengthen health outcomes for patients in low resource settings, The Max Foundation and its subsidiary, MaxAid, have signed Collaboration Agreements with 140 individual hematologists and oncologists from leading National Cancer Institutes and clinics in 60 low- and middle-income countries. With the formal establishment of this network, The Max Foundation completes its validated supply chain into each of the countries, providing a safe environment through which to channel humanitarian donations of cancer treatment with end-to-end controls.

“Oncologists and hematologists from these leading cancer centers are the true heroes of our humanitarian treatment access success story,” said Pat Garcia-Gonzalez, CEO of The Max Foundation. “Their dedication to their patients and commitment to our partnership allows us to prevent unnecessary and premature cancer deaths. Working in a challenging environment, their personal contributions go well beyond treatment management and inspire us to do our best to support their patients’ needs.”

Dr. Damira Bayzakova, Kyrgyzstan, adds that “Providing lifesaving treatment to one patient does not save the life of one patient – it saves the lives of the dozens of small children and elderly family members who depend on that patient for their survival.”

The Max Foundation aims to sign collaboration agreements with a total of 350 hematologists and oncologists from more than 70 countries in 2017.

See All News

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • Spot On CML: Improving CML Diagnostics One Patient at a Time

    Spot On CML: Improving CML Diagnostics One Patient at a Time

    February 21, 2018 · The Max Foundation and Dr. Jerry Radich of the Fred Hutchinson Cancer Research Center are partnering to help tackle the problem of access to accurate tests for chronic myeloid leukemia (CML) diagnostics in low- and middle-income countries through Spot On CML. Spot On CML is a low-cost, paper-based diagnostic testing method for CML, developed by Dr. Radich’s lab at Fred Hutch. Through a Spot On CML test, a physician spots a patient’s blood onto a paper test card and sends it to Dr. Radich’s lab for processing, where they perform accurate diagnostic testing on the samples even after weeks of transport. Once patients are diagnosed, The Max Foundation connects them with available treatments free of charge.

  • Join us November 6th for the International CML Foundation Forum at AORTIC

    Join us November 6th for the International CML Foundation Forum at AORTIC

    The African Organization for Research and Training in Cancer conference (AORTIC), happening November 5–8, 2019 brings together leading cancer specialists from around the world. During the conference, attendees are invited to join The Max Foundation and the International and Chronic Myeloid Leukemia Foundation (iCMLf) for an interactive session for African Physicians Treating CML. When: Wednesday,….

  • The Max Foundation Creates Subsidiary Organization, MaxAid, to Further Mission

    Now in its 20th year, The Max Foundation is undergoing exciting strategic changes aimed at strengthening organizational efforts to improve global access to cancer treatment, care and support. To that end, we announce the launch of MaxAid, a subsidiary organization set up by The Max Foundation to further its mission. MaxAid is a Washington nonprofit corporation with its own IRS determination letter of 501(c)(3) public charity status.